Stifel Financial
ACOR

Stifel Financial’s Acorda Therapeutics ACOR Stock Holding History

Stifel Financial’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,373
Closed -$6M – 2640
2017
Q1 		$6M Buy
2,373
+565
+31% +$1.63M 0.02% 631
2016
Q4 		$4.11M Buy
1,808
+126
+7% +$300K 0.02% 732
2016
Q3 		$4.23M Buy
1,682
+360
+27% +$1.07M 0.02% 696
2016
Q2 		$4.05M Buy
1,322
+71
+6% +$231K 0.02% 698
2016
Q1 		$3.97M Buy
1,251
+231
+23% +$959K 0.02% 635
2015
Q4 		$5.23M Buy
1,020
+132
+15% +$577K 0.03% 546
2015
Q3 		$2.82M Buy
888
+309
+53% +$1.2M 0.02% 769
2015
Q2 		$2.31M Buy
579
+57
+11% +$220K 0.01% 921
2015
Q1 		$2.08M Sell
522
-2
-0.4% -$9.16K 0.01% 924
2014
Q4 		$2.57M Buy
524
+58
+12% +$249K 0.01% 800
2014
Q3 		$1.89M Buy
466
+51
+12% +$191K 0.02% 784
2014
Q2 		$1.68M Buy
415
+28
+7% +$114K 0.02% 848
2014
Q1 		$1.76M Buy
+387
New +$1.56M 0.02% 794

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Stifel Financial's ACOR Position: Q2 2017 in Review

Stifel Financial sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 2,373 shares — an estimated $6M sold.

Stifel Financial first reported a position in ACOR in Q1 2014 and held it in 13 quarters. The position peaked at $6M in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Stifel Financial reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Stifel Financial sold 2,373 Acorda Therapeutics shares in Q2 2017, an estimated $6M.
  • Stifel Financial first reported a position in Acorda Therapeutics in Q1 2014 and held it in 13 quarters.
  • Stifel Financial's Acorda Therapeutics position peaked at $6M in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Stifel Financial's 13F filing for Q2 2017, filed 14 Aug 2017.